256 related articles for article (PubMed ID: 27211270)
21. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
Kyle RA
Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
[TBL] [Abstract][Full Text] [Related]
22. Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group.
Ong SY; de Mel S; Chen YX; Ooi MG; Surendran S; Lin A; Koh LP; Linn YC; Ho AY; Hwang WY; Phipps C; Loh SM; Goh YT; Tan D; Chng WJ; Gopalakrishnan SK
Bone Marrow Transplant; 2016 Jul; 51(7):933-7. PubMed ID: 26974274
[TBL] [Abstract][Full Text] [Related]
23. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
[TBL] [Abstract][Full Text] [Related]
24. Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis.
Thoennissen GB; Görlich D; Bacher U; Aufenberg T; Hüsken AC; Hansmeier AA; Evers G; Mikesch JH; Fritz F; Bokemeyer C; Müller-Tidow C; Stelljes M; Mesters RM; Krug U; Kropff MH; Thoennissen NH; Berdel WE
Acta Haematol; 2017; 137(3):163-172. PubMed ID: 28399522
[TBL] [Abstract][Full Text] [Related]
25. Autologous stem cell transplantation for multiple myeloma: Long-term results.
Kumar L; Boya RR; Pai R; Harish P; Mookerjee A; Sainath B; Patekar MB; Sahoo RK; Malik PS; Sharma OD; Gupta R
Natl Med J India; 2016; 29(4):192-199. PubMed ID: 28050994
[TBL] [Abstract][Full Text] [Related]
26. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
[TBL] [Abstract][Full Text] [Related]
27. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
[TBL] [Abstract][Full Text] [Related]
28. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
[TBL] [Abstract][Full Text] [Related]
29. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
[TBL] [Abstract][Full Text] [Related]
30. Rapidity and quality of response to steroid-based induction therapy, without the addition of novel agents, does not affect post transplant outcomes in multiple myeloma.
Prica A; Trieu Y; Xu W; Reece DE; Trudel S; Kukreti V; Chen C
Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):25-31. PubMed ID: 23107916
[TBL] [Abstract][Full Text] [Related]
31. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
[TBL] [Abstract][Full Text] [Related]
32. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
[TBL] [Abstract][Full Text] [Related]
33. [Therapeutic results and changes in prognosis in patients with multiple myeloma in central and northern Moravia over the past 40 years].
Scudla V; Bacovský J; Indrák K; Kod'ousková V; Vytrasová M; Faber E; Papajík T; Vavrdová V; Adam Z; Hájek R; Farbiaková V; Srovnalík K; Novosadová L; Vránová M; Micaníková M; Sumná E; Kuca B; Slezar J; Heincová V; Gumulec J; Zivná J; Schlemmer P; Lautnerová E; Lasota Z; Kubecková M; Krajsová I; Růzicka M; Cíhal K; Martínek A; Cernosek B; Doubravský J; Papajík J; Prodĕlal P
Vnitr Lek; 2002 Aug; 48(8):707-17. PubMed ID: 12425200
[TBL] [Abstract][Full Text] [Related]
34. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
35. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
36. Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience.
Lee H; Duggan P; Chaudhry A; Neri P; Tay J; Rashid-Kolvear F; Bahlis NJ; Jimenez-Zepeda VH
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e69-e75. PubMed ID: 29158114
[TBL] [Abstract][Full Text] [Related]
37. Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
Zannetti BA; Tacchetti P; Pantani L; Gamberi B; Tosi P; Rocchi S; Cellini C; Ronconi S; Pezzi A; Mancuso K; Rizzello I; Caratozzolo I; Martello M; Dozza L; Cavo M; Zamagni E
Ann Hematol; 2017 Dec; 96(12):2071-2078. PubMed ID: 29063955
[TBL] [Abstract][Full Text] [Related]
38. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Sellner L; Heiss C; Benner A; Raab MS; Hillengass J; Hose D; Lehners N; Egerer G; Ho AD; Goldschmidt H; Neben K
Cancer; 2013 Jul; 119(13):2438-46. PubMed ID: 23576287
[TBL] [Abstract][Full Text] [Related]
39. Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma.
Lee SE; Kim JH; Jeon YW; Yoon JH; Shin SH; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Lee JW; Min WS; Park CW; Min CK
Ann Hematol; 2015 Mar; 94(3):445-52. PubMed ID: 25257340
[TBL] [Abstract][Full Text] [Related]
40. Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades.
Bhatt VR; Loberiza FR; Jing H; Bociek RG; Bierman PJ; Maness LJ; Vose JM; Armitage JO; Akhtari M
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):409-415.e1. PubMed ID: 25816932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
